Potential prostate cancer patients benefit from osteoporosis drug.
Recent study: More than 100 prostate cancer patients treated with androgen deprivation therapy, which lowers testosterone levels and often causes bone loss, took either the osteoporosis drug alendronate (Fosamax) or a placebo for one year.
Result: Bone mass in the spine increased by 3.7% in those taking alendronate compared with a decline in the placebo group.
Want to Keep Reading?
Continue reading with a Health Confidential membership.
